Partnerships and collaborations enable our ability to accelerate the global investigation of novel
combination treatments that address major unmet needs and have the potential to improve outcomes for people
with cancer around the world.
Strategic partners to advance global development and commercialization
activities:
Gilead and Arcus have a 10-year all-in
partnership that includes a significant capital investment and equity stake by Gilead into Arcus.
Gilead holds co-development and co-commercialization rights to zimberelimab, domvanalimab,
etrumadenant and quemliclustat and an option to license current and future molecules.
Taiho has exercised option rights in
Japan and other countries in Asia (excluding China) for the majority of Arcus’ clinical portfolio,
including domvanalimab, zimberelimab and etrumadenant. Taiho has chosen to participate in two
ongoing Phase 3 trials of domvanalimab combinations, STAR-121 in NSCLC and STAR-221 in upper GI
cancer.
Clinical collaborations to explore novel combinations
Arcus is interested in clinical collaborations that evaluate novel combinations of Arcus molecules with other
companies’ medicines or diagnostics to expand our understanding of important pathways and facilitate
global access to expedite development and commercialization.
AstraZeneca and
Arcus have a clinical collaboration on Pacific-8 a Phase III study evaluating our anti-TIGIT
antibody domvanalimab plus durvalumab (Imfinzi®) for stage 3 non-small cell lung cancer with
curative intent
In December 2023,
Arcus and Exelixis announced a clinical trial collaboration evaluating AB521, a small molecule
inhibitor of the oxygen-sensing transcription factor HIF-2⍺, in combination with Exelixis’ tyrosine
kinase inhibitor in patients with advanced solid tumors including clear cell renal cell carcinoma
(ccRCC).